Innovation
Innovation
Providing people- and health-friendly technologies in areas ranging from ethical drugs to cosmetics and food
Providing people- and health-friendly technologies in areas ranging from ethical drugs to cosmetics and food
Self-medication
Self-medication
We are committed to advancing research and product development to meet the evolving needs of health and lifestyle over time.
We are committed to advancing research and product development to meet the evolving needs of health and lifestyle over time.
The self-medication operation group is involved in a broad range of product areas from OTC drugs (e.g., energy drinks, general cold medicines, hair care products), which are currently our staple products, to health- and beauty-related products such as food and cosmetics.
Regarding OTC drugs, we handle the transition of ethical drugs to switch OTCs. For food development, we expand the development of new products such as foods for specified health use and foods with functional claims to meet the needs of consumers. Regarding cosmetics, we established the new brand AdryS in 2019 to address women’s health issues. As shown by these examples, our new efforts also extend to product development.
Our research and development activities are based on three consumer-oriented perspectives, safety and quality, efficacy and convenience.
- Regarding safety and efficacy, we engage in the most advanced formulation activities, such as formulation design and new material development based on reliable scientific evidence or, sometimes, clinical evidence.
- Regarding quality, we introduce the latest analysis technologies based on our past accumulation of expertise in development and develop more reliable and efficient methods for quality assessment so that consumers can feel secure about using our products.
- Regarding convenience, we are always looking at matters from the consumer’s perspective and consider how our products will be used in our development of user-friendly products. We also use this approach when establishing unprecedented dosage forms and developing containers.
In research and development, we develop attractive, unique materials, conduct basic research from physiological and pathological perspectives and acquire the latest technologies in pursuit of high value-added products in consideration of the needs of consumers. Furthermore, we are actively committed to open innovation and collaboration with companies outside our group, research institutions and universities in Japan and overseas as we seek to expand our product line in areas where needs and greater growth can be expected in the future.
The self-medication operation group is involved in a broad range of product areas from OTC drugs (e.g., energy drinks, general cold medicines, hair care products), which are currently our staple products, to health- and beauty-related products such as food and cosmetics.
Regarding OTC drugs, we handle the transition of ethical drugs to switch OTCs. For food development, we expand the development of new products such as foods for specified health use and foods with functional claims to meet the needs of consumers. Regarding cosmetics, we established the new brand AdryS in 2019 to address women’s health issues. As shown by these examples, our new efforts also extend to product development.
Our research and development activities are based on three consumer-oriented perspectives, safety and quality, efficacy and convenience.
- Regarding safety and efficacy, we engage in the most advanced formulation activities, such as formulation design and new material development based on reliable scientific evidence or, sometimes, clinical evidence.
- Regarding quality, we introduce the latest analysis technologies based on our past accumulation of expertise in development and develop more reliable and efficient methods for quality assessment so that consumers can feel secure about using our products.
- Regarding convenience, we are always looking at matters from the consumer’s perspective and consider how our products will be used in our development of user-friendly products. We also use this approach when establishing unprecedented dosage forms and developing containers.
In research and development, we develop attractive, unique materials, conduct basic research from physiological and pathological perspectives and acquire the latest technologies in pursuit of high value-added products in consideration of the needs of consumers. Furthermore, we are actively committed to open innovation and collaboration with companies outside our group, research institutions and universities in Japan and overseas as we seek to expand our product line in areas where needs and greater growth can be expected in the future.
Prescription pharmaceutical operation business
Prescription pharmaceutical operation business
We engage in strategic research and development as we move toward another stage of growth.
We engage in strategic research and development as we move toward another stage of growth.
Taisho Pharmaceutical’s prescription pharmaceutical operation group dates back to 1957 when the Company released Psorion, a psoriasis medicine and our first ethical drug in the field of dermatology, and we then expanded into the market of ethical drugs based on our track record in the skin disease medicine Dermarin following an increase in demand for ethical drugs that resulted from the implementation of universal health insurance.
As an R&D-oriented company, we strive to discover self-developed drugs. In 1991, we released Clarith, a macrolide antibiotic which has been made available in 130 countries to date. We also launched Lusefi, a type 2 diabetes medicine we created, and the transdermally absorbable anti-inflammatory analgesic Loqoa in 2014 and 2016, respectively.
In 2022, we released Nanozora 30-milligram subcutaneous injection syringe, a TNFα inhibitor introduced by Ablynx and the first next-generation VHH antibody drug in Japan. Nanozora 30-milligram Autoinjector for S.C. Injection was launched in the following year, 2023. Our research into antibodies has been intensifying.
We strive to research and develop unique new drugs through efforts such as the utilization of advanced technologies and greater collaboration with outside research institutions. Recently, we focus on drug discovery research using next-generation VHH antibodies.
While trying to obtain the approval of our pipeline drugs as quickly as possible, we are strengthening our pipelines through licensing activities.
Taisho Pharmaceutical’s prescription pharmaceutical operation group dates back to 1957 when the Company released Psorion, a psoriasis medicine and our first ethical drug in the field of dermatology, and we then expanded into the market of ethical drugs based on our track record in the skin disease medicine Dermarin following an increase in demand for ethical drugs that resulted from the implementation of universal health insurance.
As an R&D-oriented company, we strive to discover self-developed drugs. In 1991, we released Clarith, a macrolide antibiotic which has been made available in 130 countries to date. We also launched Lusefi, a type 2 diabetes medicine we created, and the transdermally absorbable anti-inflammatory analgesic Loqoa in 2014 and 2016, respectively.
In 2022, we released Nanozora 30-milligram subcutaneous injection syringe, a TNFα inhibitor introduced by Ablynx and the first next-generation VHH antibody drug in Japan. Nanozora 30-milligram Autoinjector for S.C. Injection was launched in the following year, 2023. Our research into antibodies has been intensifying.
We strive to research and develop unique new drugs through efforts such as the utilization of advanced technologies and greater collaboration with outside research institutions. Recently, we focus on drug discovery research using next-generation VHH antibodies.
While trying to obtain the approval of our pipeline drugs as quickly as possible, we are strengthening our pipelines through licensing activities.
